How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

865 results for

Endocrine Manifestations of HIV

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes

cotransport-2 inhibitors (SGLT-2). Treatment with any of these drugs should have been stopped at least 3 months before inclusion. Current or recent (within past 30 days) participation in another investigational drug or device study. Have participated in a previous study of BTI320. Have any uncontrolled cardiovascular risk factors (hypertension, hyperlipidemia), past clinical manifestation of coronary artery disease, blood dyscrasias, or significant cerebrovascular disease in the previous year. Any (...) immunodeficiency virus (HIV) infection, hepatitis, tuberculosis, or other serious infectious disease. History of alcohol addiction or drug abuse (illegal or controlled pharmaceutical substances) within past year prior to randomization. Have planned major surgery within 6 months after randomization. Have a terminal illness. Serum creatinine of >1.4 mg/dL (>124 μmol/L) in women or >1.5 mg/dL (>133 μmol/L) in men or subjects with end-stage renal disease (Estimated Glomerular Filtration Rate calculated by CKD-EPI

2018 Clinical Trials

162. Personalized Nutrition for Diabetes Type 2

to amputations. It is also linked to other manifestations, collectively termed the metabolic syndrome, including obesity, hypertension, non-alcoholic fatty liver disease, hypertriglyceridemia and cardiovascular disease . As blood glucose levels are mainly affected by food consumption, the growing number of blood glucose abnormalities is likely attributable to nutrition. Indeed, dietary and lifestyle changes normalize blood glucose levels in 55% -80% of the cases. Therefore, maintaining normal blood glucose (...) of the recommended daily consumption At least 2 reported meals a day Exclusion Criteria: Short-acting insulin treatment Bariatric surgery Antibiotics/antifungal treatment in the last 3 months Use of weight-loss medication for less than 6 months Use of GLP-1 and SGLT-2 for less than 6 months People under another diet regime that is different from the ADA recommended diet Pregnancy or 3 months after giving birth, fertility treatments Chronic disease (e.g. HIV, Cushing syndrome, CKD, acromegaly, active

2018 Clinical Trials

163. Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy

or not clinically significant. Electrocardiogram (ECG), AST, ALT, and urinalysis values within the normal range for the testing facility or not clinically significant. Normal renal function: Glomerular filtration rate (GFR) calculated by Cockcroft-Gault formula > 60 ml/min. Negative pregnancy test within 1 week of Segment 1, Study Day 1. Negative urine test for substances of abuse per CRU standards. Negative serology tests for HIV, hepatitis B surface antigen, and hepatitis C virus antibody. Body Mass Index (...) ) Sharing Statement: Plan to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Syntrix Biosystems, Inc.: Analgesia Additional relevant MeSH terms: Layout table for MeSH terms Neuralgia Diabetic Neuropathies Chronic Pain Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Diabetes Complications Diabetes

2018 Clinical Trials

164. Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

, and/or consolidation/maintenance therapy. Chemotherapy administered in conjunction with primary radiation as a radiosensitizer WILL be counted as a systemic chemotherapy regimen. Patients are not required to, but may have received a single line of prior hormonal therapy with either an antiestrogen, anti progesterone (or combination) or an aromatase inhibitor. Patients may not have received more than 1 line of endocrine therapy. This will not count toward prior therapy total. Resolution of adverse effects of recent (...) [HCV] antibody serology testing) Patients positive for anti-HBc are eligible only if also positive for HB surface antibody (anti-HBs) and polymerase chain reaction (PCR) assay is negative for HBV DNA. Patients positive for HCV antibody are eligible only if testing for HCV RNA is negative. Known HIV infection. Active autoimmune disease that is not controlled by nonsteroidal anti -inflammatory drugs. Pregnancy, lactation, breastfeeding. Current severe, uncontrolled systemic disease (e.g., clinically

2018 Clinical Trials

165. Carvedilol in Treating Hypoglycemia Unawareness

Mellitus β-blocker Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus, Type 1 Hypoglycemia Unconsciousness Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Consciousness Disorders Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms Carvedilol Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular (...) (3 or more) or insulin pump therapy Negative pregnancy test Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines Exclusion Criteria: Major medical disorders (including liver disease, cardiovascular disease, kidney disease, chronic obstructive pulmonary disease, asthma, active malignancy or HIV) Overt diabetes complications (neuropathy, nephropathy, retinopathy) Presence of anemia Current or recent use of beta-blocker

2018 Clinical Trials

166. Pharmacokinetics of Two Formulation of Pregabalin

Diabetic Neuropathies Epilepsy Epilepsies, Partial Neurologic Manifestations Nervous System Diseases Signs and Symptoms Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases Brain Diseases Central Nervous System Diseases Pregabalin Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anticonvulsants Calcium Channel Blockers Membrane Transport Modulators Molecular (...) in the study. Exclusion Criteria: A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the investigator). A clinically significant illness or surgery within four weeks prior to study drug dosing (as determined by the investigator). History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last

2018 Clinical Trials

167. Lentiviral Gene Therapy for X-ALD

of the MRI to examine the damage on the CNS. Neurological function score (NFS) ≥ 1 Parent / guardian / patient signing informed consent Patients and their families have a strong willingness to participate in clinical trials, and are willing to bear all the consequences caused by the failure of the trial, and sign an informed consent form Exclusion Criteria: HIV positive patients Stablized condition after statins, Lorenzoas oil, or diet to reduce VLCFA levels Patients who are experiencing severe viral (...) Adrenoleukodystrophy Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Hereditary Central Nervous System Demyelinating Diseases Leukoencephalopathies Demyelinating Diseases Mental Retardation, X-Linked Intellectual Disability Neurobehavioral Manifestations Neurologic Manifestations Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolism, Inborn Errors Peroxisomal Disorders Metabolic

2018 Clinical Trials

168. The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults

Diabetes Mellitus Diabetes Mellitus, Type 2 Atrophy Muscular Atrophy Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Pathological Conditions, Anatomical Neuromuscular Manifestations Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit. Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV. Participant is an amputee and/or has presence of partial or full artificial limb. Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease

2018 Clinical Trials

169. Clinical Evaluation of CelluTite Treatment

, silicone implants or an injected chemical substance. Current or history of skin cancer (remission of 5 years), or current condition of any other type of cancer, or pre-malignant moles. Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. Pregnancy and nursing. History of bleeding coagulopathies or use of anticoagulants. Impaired immune system due to immunosuppressive diseases such as AIDS and HIV or use of immunosuppressive (...) medications. Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. Use of Isotretinoin (Accutane®) within 6 months prior to treatment. Any surgery or treatment such as laser or chemicals in treated area within 3-6 months prior to treatment or before complete healing

2018 Clinical Trials

170. Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®): Health Professional Version

. Radiation-induced damage also differs from chemotherapy-induced changes in that irradiated tissue tends to manifest permanent damage that places the patient at continual risk for oral sequelae. The oral tissues are thus more easily damaged by subsequent toxic drug or radiation exposure, and normal physiologic repair mechanisms are compromised as a result of permanent cellular damage. References Larson PJ, Miaskowski C, MacPhail L, et al.: The PRO-SELF Mouth Aware program: an effective approach (...) , bacterial). Chronic GVHD. Dental/skeletal growth and development alterations (pediatric patients). Xerostomia. Relapse-related oral lesions. Second malignancies. Phase V: Long-term Survival Relapse or second malignancies. Dental/skeletal growth and development alterations. GVHD = graft-versus-host disease. Phase I: Before Chemotherapy Oral complications are related to current systemic and oral health, oral manifestations of underlying disease, and oral complications of recent cancer or other medical

2016 PDQ - NCI's Comprehensive Cancer Database

171. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

intrachromosomal rearrangements, are frequently found; among them, RET/PTC rearrangements are the most common.[ ] Genetic inheritance. Genetic inheritance plays a role in a subset of thyroid carcinomas. In children, medullary thyroid carcinoma is caused by a dominantly inherited or de novo gain-of-function mutation in the RET proto-oncogene associated with multiple endocrine neoplasia (MEN) type 2, either MEN2A or MEN2B, depending on the specific mutation.[ ] When occurring in patients with the MEN syndromes (...) carcinoma: Medullary thyroid carcinoma is a rare form of thyroid carcinoma that originates from the calcitonin-secreting parafollicular C cells and accounts for less than 10% of all cases of thyroid carcinoma in children.[ ] In children, medullary thyroid carcinoma is usually associated with RET germline mutations in the context of multiple endocrine neoplasia type 2 syndrome.[ ] Anaplastic carcinoma: Less than 1% of pediatric thyroid carcinomas are anaplastic carcinoma. Molecular Features Thyroid

2016 PDQ - NCI's Comprehensive Cancer Database

172. Childhood Vascular Tumors Treatment (PDQ®): Health Professional Version

of the upper medial eyelid but any hemangioma around the eye that is large enough can obstruct the visual axis. The clinician should be aware of subcutaneous periocular hemangiomas, as these lesions can extend into the orbit, causing exophthalmos or globe displacement with only limited cutaneous manifestations. Issues with these lesions include astigmatism from direct pressure of the growing hemangioma, ptosis, proptosis, and strabismus. One of the leading causes of preventable blindness in children (...) in children with facial hemangiomas and PHACE association. Pediatrics 117 (3): 959-64, 2006. [ ] Heyer GL, Dowling MM, Licht DJ, et al.: The cerebral vasculopathy of PHACES syndrome. Stroke 39 (2): 308-16, 2008. [ ] Haggstrom AN, Garzon MC, Baselga E, et al.: Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 126 (2): e418-26, 2010. [ ] Poindexter G, Metry DW, Barkovich AJ, et al.: PHACE syndrome with intracerebral hemangiomas, heterotopia, and endocrine dysfunction. Pediatr

2016 PDQ - NCI's Comprehensive Cancer Database

173. Heidelberg Study on Diabetes and Complications

Accepts Healthy Volunteers: Yes Sampling Method: Non-Probability Sample Study Population Study Population comprises patients with Diabetes, patients with pre-diabetes, and healthy controls. In total, 500 participants shall be enrolled and observed for 10 years. Criteria Inclusion Criteria Age between 18 and 75 years Persons with manifest diabetes mellitus type 1 or type 2 and diagnosis according to DDG guidelines 2011, that is HbA1c of 6,5 percent or higher after exclusion of false values, more than (...) , Wilsons disease, hemochromatosis, autoimmune hepatitis severe peripheral artery disease stadium IV non diabetic glomerulopathy Cancer or other malignant diseases within the last 5 years Infectious diseases like hepatitis B, C, E, or HIV Other severe autoimmune diseases Current participation in an interventional study Anemia or disorders of bone marrow Exclusion criteria for MRI Pacemaker or ICD Metallic and magnetic implants, for example mechanic cardiac valves replacements, joint prostheses, clips

2017 Clinical Trials

174. GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes

Kidney Diseases Albuminuria Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Urologic Diseases Proteinuria Urination Disorders Urological Manifestations Signs and Symptoms Exenatide Hypoglycemic Agents Physiological Effects of Drugs Anti-Obesity Agents Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists (...) antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody Liver function tests more than 3 times the upper limit of normal Renal impairment (serum eGFR <30 ml/min) HIV Inability to give informed consent History of gastroparesis History of medullary thyroid carcinoma or MEN 2 syndrome Alcoholism Hypertriglyceridemia (>500 mg/dl). Any other life-threatening, non-cardiac disease Uncontrolled hypertension (BP > 160/100 mm of Hg) Congestive Heart Failure class III or IV Use

2017 Clinical Trials

175. International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

) and the occurrence of systemic and local post-vaccination reactions in comparison with placebo epidemiological effectiveness of vaccination [ Time Frame: through study completion, an average of 1 year" ] 2. Where possible, to evaluate epidemiological effectiveness of vaccination based on the follow-on morbidity indicators of immunized and non-immunized individuals, manifestations of the epidemiological process in time and space Eligibility Criteria Go to Information from the National Library of Medicine Choosing (...) for pregnancy (for child-bearing age females) not more than 24 hours prior to the administration of the first dose of investigated product; absence of concomitant illnesses, especially dangerous or endemic for a particular region, proved by laboratory and/or clinical methods (malaria, yellow fever, Denge fever, Ebola or Marburg virus disease, poliomyelitis). negative results of HIV, hepatitis B and C and syphilis tests. adequate contraception for females and males of reproductive age. negative results

2017 Clinical Trials

176. PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)

to chimeric, human or humanized antibodies, or fusion proteins. Known hypersensitivity to CHO cell products or any component of the atezolizumab formulation. History of any of the following cardiovascular conditions within 6 months prior to the first dose of study treatment: Unstable angina. Clinically significant cardiac arrhythmias. Myocardial infarction. Have current or recent (past 6 months) history of severe, progressive, or uncontrolled renal, hepatic, gastrointestinal, metabolic, endocrine (...) , antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions: Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g

2017 Clinical Trials

177. Mass Balance Study With MT-8554

, whichever is longer) prior to dosing unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study procedures or compromise subject safety. 7. Clinically significant (in the opinion of the Investigator) endocrine, thyroid, hepatic (including Gilbert's syndrome), respiratory, gastrointestinal, renal, cardiovascular disease or history (within the last 2 years) of any significant psychiatric/psychotic illness disorder (including anxiety, depression and reactive (...) or one measure (25 mL) of spirits or one glass (125 mL) of wine. 18. Subjects who use tobacco or nicotine-containing products (cigarettes, snuff, chewing tobacco, cigars, pipes, e cigarettes or nicotine-replacement products) within 3 months prior to dosing, or positive urine cotinine test at Screening or Day 1. 19. Test positive for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody or human immunodeficiency virus (HIV) 1 and HIV 2 antibodies at Screening. 20. Donate one

2017 Clinical Trials

178. Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Positive for hepatitis C antigen at or within 30 days of screening Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease. History of HIV (as determined by medical records or patient reported). History of diverticulitis or chronic, ulcerative lower gastrointestinal (GI) disease such as Crohns disease, ulcerative colitis, or other symptomatic, lower GI conditions that might predispose (...) for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Diagnosis of systemic sclerosis (SSc), as classified using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc. Diffuse Cutaneous Systemic Sclerosis (dcSSc) as defined by 2001 LeRoy and Medsger Disease duration ≤ 60 months (defined as time from the first non−Raynaud phenomenon manifestation) Modified Rodnan Skin Score (mRSS) units ≥ 10 and ≤ 45 at screening. Agreement

2017 Clinical Trials

179. Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

meter of body-surface area or its equivalent Prior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic disease Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years (...) manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations Rash must cover less than 10% of body surface area (BSA) Disease is well controlled at baseline and only requiring low-potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05

2017 Clinical Trials

180. Putative Cognitive Enhancer VU319

or Dejection, Confusion or Bewilderment. A five-point scale ranging from "not at all" to "extremely" is administered by experimenters to patients to assess their mood states. Behavioral Measure - Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Baseline, 1, 3, and 7 hour post drug administration ] Persons having or suspected of having schizophrenia or other psychotic disorder manifest the disorder in multiple ways. The BPRS assesses the level of 24 symptom constructs such as hostility, suspiciousness (...) and human immunodeficiency virus (HIV-1 or HIV-2) antibody at screening. Nonsmokers (use of any nicotine containing product) or ex-smokers (have ceased smoking for at least 6 months and do not use any drug for smoking cessation). Negative screen for alcohol and drugs of abuse at screening and admission. For Women: Must have no child-bearing potential by reason of surgery or at least 1 year post-menopausal (i.e. 12 months without menstrual period), or menopause confirmed with an estradiol level of < 30

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>